Fig. 2

Efficacy and safety of the miriplatin-TOCE/DDP-H-HAIC combination therapy compared with the miriplatin-TOCE monotherapy. a Progression free survival time was significantly longer in the combination therapy group (p < 0.001; continuous line, combination therapy; dotted line, monotherapy). b Time dependent changes of des-γ-carboxyprothrombin (DCP) after each session. The relative DCP is a percentage of the log scale DCP value after treatments versus that obtained before the initial treatment (open circles, combination therapy (p = 0.034, r = 0.33); closed triangles, monotherapy (p < 0.0001, r = 0.80)). The continuous lines are the best hit lines accompanied with dotted lines showing 95% confidence intervals. The black and grey colors indicate the combination and monotherapies, respectively. c Kaplan-Meier estimates of overall survival were not significantly different between the two arms (p = 0.34, continuous line, combination therapy; dotted line, monotherapy). d Time-dependent changes in the serum concentrations of cholinesterase (ChE). Each value represents a percentage of the serum concentration of ChE versus the value obtained before the initial treatment. The circles and triangles represent the combination and monotherapies, respectively. The open mark shows the values from the cases, in which ChE never decreased to less than 80% of the values obtained before the initial treatments. In the closed marks, ChE did decrease to less than 80% of the initial values. The dotted horizontal line represents the 80% cutoff. The continuous line is the best hit line for the closed circular values with the dotted diagonal line that demonstrates 95% confidence intervals (p < 0.0001, r = −0.86). The number of cases in each arm was shown as “n=”